The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 21, 2006
Filed:
Aug. 01, 2003
Joerg Martin Bentzien, White Plains, NY (US);
Brian Nicholas Cook, Danbury, CT (US);
Charles Cywin, Bethel, CT (US);
Roman Wolfgang Fleck, Greenwich, CT (US);
Ho Yin Lo, Bethel, CT (US);
Peter Allen Nemoto, Southbury, CT (US);
Steven S. Pullen, Danbury, CT (US);
Gregory Paul Roth, Woodstock, CT (US);
Roger John Snow, Danbury, CT (US);
Hidenori Takahashi, LaGrangeville, NY (US);
Ji Wang, Danbury, CT (US);
Kevin J. Moriarty, East Norriton, PA (US);
Lei Qiao, Downingtown, PA (US);
Michael Winters, Morgantown, PA (US);
Joerg Martin Bentzien, White Plains, NY (US);
Brian Nicholas Cook, Danbury, CT (US);
Charles Cywin, Bethel, CT (US);
Roman Wolfgang Fleck, Greenwich, CT (US);
Ho Yin Lo, Bethel, CT (US);
Peter Allen Nemoto, Southbury, CT (US);
Steven S. Pullen, Danbury, CT (US);
Gregory Paul Roth, Woodstock, CT (US);
Roger John Snow, Danbury, CT (US);
Hidenori Takahashi, LaGrangeville, NY (US);
Ji Wang, Danbury, CT (US);
Kevin J. Moriarty, East Norriton, PA (US);
Lei Qiao, Downingtown, PA (US);
Michael Winters, Morgantown, PA (US);
Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT (US);
Abstract
Disclosed are substituted benzimidazole compounds of formula (I): wherein R, R, R, Rand Xare defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.